Previous 10 | Next 10 |
Rockwell Medical (RMTI) has submitted a pre-IND meeting request with the FDA in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate ((FPC)), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in ...
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a p...
Rockwell Medical ([[RMTI]] +6.7%) has extended its distribution agreement with its long-term distribution partner, Nipro Medical Corporation (NMC), for a period of three years through May 2024.With the extension of the original agreement signed in 2008, NMC will continue to distribute dialysi...
WIXOM, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it extended its dist...
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead to transformative treatments for iron deficiency in multiple disease st...
Rockwell Medical (RMTI) perks up 6% premarket after entering into an exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic AVNU (ferric pyrophosphate citrate injection) in Turkey. Under the terms of the license agreement, Drogsan will...
WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan Pharmaceut...
WIXOM, Mich., June 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its execu...
The #nextmove in a #stockprice is often identifiable in advance. This Rockwell Medical (NASDAQ: RMTI) report attempts to do that, and in the process help investors learn how price acton can be revealing. Trading plans for RMTI make these observations actionab...
The following slide deck was published by Rockwell Medical, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Rockwell Medical, Inc. 2021 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Rockwell Medical Inc. Company Name:
RMTI Stock Symbol:
NASDAQ Market:
Rockwell Medical Inc. Website:
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the ...